Drug profile

The FDA adverse-event record for Bovine Rhinotracheitis-Virus Diarrhea Vaccine

12 FDA reports name Bovine Rhinotracheitis-Virus Diarrhea Vaccine, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2323 of 2,679
by report volume (all drugs)
12
adverse-event reports
100.0%
death-coded share
Cattle
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Bovine Rhinotracheitis-Virus Diarrhea Vaccine ranks #2299 of 2679 by total reports (12). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2299
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Bovine Rhinotracheitis-Virus Diarrhea Vaccine has 12 reports now versus 12 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Bovine Rhinotracheitis-Virus Diarrhea Vaccine changes

Signature read: Bovine Rhinotracheitis-Virus Diarrhea Vaccine's 100.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
12
Deaths Reported
100.0%
Death-coded share of reports

Active Ingredients

Bovine Rhinotracheitis-Virus Diarrhea Vaccine

Administration Routes

UnknownParenteralSubcutaneous

Species Affected

Cattle 12

Most Affected Breeds

Crossbred Bovine/Cattle 7
Cattle (unknown) 4
Holstein-Friesian also known as Holstein 1

Most Reported Reactions

Death 12
Respiratory tract disorder NOS 6
Behavioural disorder NOS 6
Unclassifiable adverse event 6
Weight gain 4
Digestive tract disorder NOS 4
Acute (interstitial) pneumonia/pleuropneumonia 3
NT - Abnormal necropsy finding NOS 2
Respiratory signs 2
Myocarditis 2
Lack of efficacy - NOS 1
Pneumonia 1

Outcome Breakdown

Died
12 (54.5%)
Outcome Unknown
7 (31.8%)
Ongoing
2 (9.1%)
Euthanized
1 (4.5%)

Bovine Rhinotracheitis-Virus Diarrhea Vaccine: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Bovine Rhinotracheitis-Virus Diarrhea Vaccine (#2323 of 2,679 by report volume); death-coded 100.0%. PlainBreed drug row · death-coded share stamp 100.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →